NCT06093776 is a clinical trial of ioveraº system in Pain Management Improvement, sponsored by Methodist Health System.

Who is sponsoring NCT06093776?

NCT06093776 is sponsored by Methodist Health System.

What drugs are being tested in NCT06093776?

Interventions in NCT06093776: ioveraº system.

What condition does NCT06093776 study?

NCT06093776 studies Pain Management Improvement.

Is NCT06093776 still recruiting?

NCT06093776 is currently completed. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT06093776

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rib Fracture Cryoanalgesia

Completed Last updated 23 March 2026

What this trial tests

trial testing ioveraº system in Pain Management Improvement in 5 participants. Completed in 12 June 2025.

Timeline

5 June 2023

Primary endpoint
12 June 2025

12 June 2025

Quick facts

Lead sponsor	Methodist Health System
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5
Start date	5 June 2023
Primary completion	12 June 2025
Estimated completion	12 June 2025
Sites	1 location across United States

Drugs / interventions tested

ioveraº system

Conditions studied

Pain Management Improvement — all drugs for Pain Management Improvement →

Sponsor

Methodist Health System — full company profile →

Who can join

Adults 18 to 75, any sex, with Pain Management Improvement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rib fractures lead to poor patient outcomes and even death 3. Data suggests effective pain management is crucial to obtain favorable outcomes 4, 5Current outpatient treatment modalities are limited to oral or topical medications with low efficacy and high risk for opioid dependence. In-patient management with a thoracic epidural TEA is largely considered the gold standard, but the risks of TEA may outweigh the benefits 6 to 8.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Methodist Health System trials

Trials by the same sponsor.

NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
NCT07492758 — Management of Extremity Injuries Registry · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06093776 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06093776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing